Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta‐analysis and meta‐regression analysis

Antipsychotic polypharmacy in schizophrenia is much debated, since it is common and costly with unclear evidence for its efficacy and safety. We conducted a systematic literature search and a random effects meta‐analysis of randomized trials comparing augmentation with a second antipsychotic vs. con...

Full description

Saved in:
Bibliographic Details
Published in:World psychiatry 2017-02, Vol.16 (1), p.77-89
Main Authors: Galling, Britta, Roldán, Alexandra, Hagi, Katsuhiko, Rietschel, Liz, Walyzada, Frozan, Zheng, Wei, Cao, Xiao‐Lan, Xiang, Yu‐Tao, Zink, Mathias, Kane, John M., Nielsen, Jimmi, Leucht, Stefan, Correll, Christoph U.
Format: Article
Language:English
Subjects:
Antipsychotics
aripiprazole
augmentation
clozapine
monotherapy
polypharmacy
Psychotropic drugs
Quality
Research Report
Research Reports
Schizophrenia
Studies
Systematic review
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Antipsychotic polypharmacy in schizophrenia is much debated, since it is common and costly with unclear evidence for its efficacy and safety. We conducted a systematic literature search and a random effects meta‐analysis of randomized trials comparing augmentation with a second antipsychotic vs. continued antipsychotic monotherapy in schizophrenia. Co‐primary outcomes were total symptom reduction and study‐defined response. Antipsychotic augmentation was superior to monotherapy regarding total symptom reduction (16 studies, N=694, standardized mean difference, SMD=–0.53, 95% CI: −0.87 to −0.19, p=0.002). However, superiority was only apparent in open‐label and low‐quality trials (both p
ISSN:1723-8617
2051-5545
DOI:10.1002/wps.20387